IRLAB Therapeutics AB (publ) (ST:IRLAB-A) — Market Cap & Net Worth
Market Cap & Net Worth: IRLAB Therapeutics AB (publ) (IRLAB-A)
IRLAB Therapeutics AB (publ) (ST:IRLAB-A) has a market capitalization of $11.36 Million (Skr105.56 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26738 globally and #581 in its home market, demonstrating a 0.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IRLAB Therapeutics AB (publ)'s stock price Skr1.24 by its total outstanding shares 84858244 (84.86 Million). Review IRLAB-A total debt and obligations to assess the company's total debt and financial obligations.
IRLAB Therapeutics AB (publ) Market Cap History: 2017 to 2026
IRLAB Therapeutics AB (publ)'s market capitalization history from 2017 to 2026. Data shows change from $256.64 Million to $11.36 Million (-21.33% CAGR).
IRLAB Therapeutics AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IRLAB Therapeutics AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.31x
IRLAB Therapeutics AB (publ)'s market cap is 0.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $256.64 Million | $109.00K | -$56.23 Million | 2354.53x | N/A |
| 2018 | $565.33 Million | $18.00K | -$74.10 Million | 31407.43x | N/A |
| 2019 | $328.43 Million | $26.00K | -$96.32 Million | 12632.02x | N/A |
| 2020 | $383.55 Million | $300.00K | -$91.85 Million | 1278.49x | N/A |
| 2021 | $401.81 Million | $207.78 Million | $51.78 Million | 1.93x | 7.76x |
| 2022 | $349.76 Million | $61.14 Million | -$114.20 Million | 5.72x | N/A |
| 2023 | $68.49 Million | $5.68 Million | -$177.84 Million | 12.06x | N/A |
| 2024 | $98.17 Million | $94.63 Million | -$83.13 Million | 1.04x | N/A |
| 2025 | $17.99 Million | $57.46 Million | -$110.01 Million | 0.31x | N/A |
Competitor Companies of IRLAB-A by Market Capitalization
Companies near IRLAB Therapeutics AB (publ) in the global market cap rankings as of June 19, 2026.
Key companies related to IRLAB Therapeutics AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
IRLAB Therapeutics AB (publ) Historical Marketcap From 2017 to 2026
Between 2017 and today, IRLAB Therapeutics AB (publ)'s market cap moved from $256.64 Million to $ 11.36 Million, with a yearly change of -21.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr11.36 Million | -36.85% |
| 2025 | Skr17.99 Million | -81.67% |
| 2024 | Skr98.17 Million | +43.33% |
| 2023 | Skr68.49 Million | -80.42% |
| 2022 | Skr349.76 Million | -12.95% |
| 2021 | Skr401.81 Million | +4.76% |
| 2020 | Skr383.55 Million | +16.78% |
| 2019 | Skr328.43 Million | -41.90% |
| 2018 | Skr565.33 Million | +120.28% |
| 2017 | Skr256.64 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of IRLAB Therapeutics AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.36 Million USD |
| MoneyControl | $11.36 Million USD |
| MarketWatch | $11.36 Million USD |
| marketcap.company | $11.36 Million USD |
| Reuters | $11.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pir… Read more